Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors

Abstract

Receptor tyrosine kinases are critical for the growth and proliferation of many different cancers and therefore represent a potential vulnerability that can be therapeutically exploited with small molecule inhibitors. Over forty small molecule inhibitors are currently approved for the treatment of adult solid tumors. Their use has been more limited in pediatric solid tumors, although an increasing number of single-agent and combination studies are now being performed. These agents have been quite successful in certain clinical contexts, such as the treatment of pediatric tumors driven by kinase fusions or activating mutations. By contrast, only modest activity has been observed when inhibitors are used as single agents for solid tumors that do not have genetically defined alterations in the target genes. The absence of predictive biomarkers has limited the wider applicability of these drugs and much work remains to define the appropriate patient population and clinical situation in which receptor tyrosine kinase inhibitors are most beneficial. In this manuscript, we discuss these issues by highlighting past trials and identifying future strategies that may help add precision to the use of these agents for pediatric extracranial solid tumors.

Sustained Response with Dose Reduced Selpercatinib in a Pediatric Patient with Metastatic NCOA4-RET Fusion Papillary Thyroid Carcinoma

“…More precise administration of tyrosine kinase inhibitors is being studied, and it is proposed that the wider therapeutic index of targeted agents may allow for pediatric dosing to be less than the maximum tolerated dose documented in adults. 19 In summation, a better understanding of the molecular landscape of pediatric PTC offered an effective systemic treatment modality, and we will continue to closely observe the dose response in our patient.…”

The role of angiogenesis in melanoma: Clinical treatments and future expectations

“…Tyrosine kinase inhibitors (TKIs) are involved in tumorigenesis and progression, which aims to inhibits the catalytic function of kinases and then blocks the activation of downstream signaling cascade ( Bellantoni and Wagner, 2021 ; Salmaso et al, 2021 ). In recent years, TKIs have identified as critical targets for drug discovery ( Choi et al, 2021 ; Mohammadi and Gelderblom, 2021 ; Yang et al, 2022 ).…”

The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma

“…Kinase inhibitors have developed into one of the standard drug classes in the repertoire of personalized oncology [36,37], and a multitude of kinase inhibiting compounds has been tested preclinically in MB, most of them targeting enzymes that are involved in cell cycle regulation. However, activating mutations in receptor tyrosine kinases, which are frequently detected in other CNS malignancies such as glioblastoma, are rare in MB [8].…”